David Ricks, Chair and C.E.O. of Eli Lilly and Company, speaks during the New York Times annual DealBook summit at Jazz at ...

David Ricks thinks Trump's tariffs will eventually target drugmakers. The results could be harmful to them in more ways than one. Despite this issue, Eli Lilly remains a top stock to buy.

Presiding over the upward trajectory of Eli Lilly over the last eight years has been paying off nicely for CEO David Ricks. In 2024, his compensation package grew to $29.2 million, according to ...

When David Ricks became CEO of Eli Lilly, he faced the usual pressures of making the right, albeit risky, bets on the next big pharmaceutical breakthrough. But he also faced a unique challenge—t ...

Eli Lilly is getting closer to bringing a weight loss pill to market, but CEO David Ricks notes certain factors need to be considered to prevent prices from ballooning. The Trump administration ...

Eli Lilly has seen positive results from a phase 3 trial of Orforglipron, the first-ever GLP-1 pill for weight loss and type 2 diabetes. Previous versions were administered via injection.

And that’s at GLP-1, and Lilly got the big lead. David Ricks is a visionary. We stay long that stock.” “I think that Eli Lilly is probably one of the least tariffed, least dangerous stocks.

May 8, 2025 – Today, TIME reveals the second annual TIME100 Health list recognizing the 100 most influential individuals in ...

Eli Lilly (LLY) CEO David Ricks got a 10% raise in 2024, as a surge in demand for weigh-loss drugs has propelled the pharma giant into the most valuable pharmaceutical company in the world.

However, some major executives in the sector are not optimistic, including Eli Lilly's (NYSE: LLY) CEO, David Ricks. Start Your Mornings Smarter! Wake up with Breakfast news in your inbox every ...

However, some major executives in the sector are not optimistic, including Eli Lilly's (NYSE: LLY) CEO, David Ricks. Let's see what he had to say about the potential impact of tariffs, and what ...